We were disappointed to hear that on August 1, 2019 BioMarin announced plans to discontinue preclinical studies in the BMN 290 programme for Friedreich’s Ataxia. BMN 290 is a selective chromatin modulation therapy that has been under investigation as an active preclinical programme since 2017.
Posted 02/08/2019
Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.
To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia
Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.
